Top Page
Bubs Australia Ltd.
(Sydney:BUB)
Bubs Australia Ltd. (BUB) vs. iShares MSCI Australia ETF (EWA)
Bubs Australia Ltd. Business Overview & Revenue Model
Bubs Australia Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.54M | 102.54M | 79.70M | 60.11M | 89.30M | 39.31M |
| Gross Profit | 49.06M | 49.06M | 38.70M | -11.68M | 26.21M | -10.68M |
| EBITDA | 4.92M | 4.92M | -19.42M | -104.29M | -7.82M | -73.04M |
| Net Income | 5.54M | 5.54M | -20.99M | -108.35M | -11.38M | -74.74M |
Balance Sheet | ||||||
| Total Assets | 57.17M | 57.17M | 66.75M | 65.60M | 125.94M | 105.92M |
| Cash, Cash Equivalents and Short-Term Investments | 17.43M | 17.43M | 17.52M | 26.05M | 16.31M | 27.88M |
| Total Debt | 967.50K | 967.50K | 7.00M | 4.41M | 4.92M | 4.16M |
| Total Liabilities | 14.69M | 14.69M | 29.88M | 23.92M | 37.73M | 18.90M |
| Stockholders Equity | 42.48M | 42.48M | 36.87M | 41.68M | 88.21M | 87.02M |
Cash Flow | ||||||
| Free Cash Flow | 6.05M | 6.05M | -26.52M | -46.74M | -9.93M | -23.24M |
| Operating Cash Flow | 6.13M | 6.13M | -26.33M | -46.49M | -9.37M | -22.63M |
| Investing Cash Flow | -118.11K | -118.11K | -189.82K | -4.25M | -1.56M | -5.60M |
| Financing Cash Flow | -6.03M | -6.03M | 17.99M | 60.48M | -643.21K | 30.09M |
Bubs Australia Ltd. Technical Analysis
Bubs Australia Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$116.06M | 16.55 | 10.07% | 2.67% | 38.25% | 361.54% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | AU$134.12M | 24.19 | 13.97% | ― | 28.66% | ― | |
51 Neutral | AU$38.70M | -1.68 | -31.14% | ― | -15.07% | 29.50% | |
45 Neutral | AU$23.34M | -5.75 | -29.43% | ― | 102.21% | 69.47% | |
40 Underperform | AU$36.02M | -0.24 | ― | ― | 1.03% | -52.56% | |
38 Underperform | AU$28.25M | ― | -20.54% | ― | 13.92% | 36.28% |
Bubs Australia Ltd. Corporate Events
Bubs Australia Limited has announced an update on its legal dispute involving its subsidiary, The Infant Food Co. Pty Limited, against former customers Alice Trading Limited and Willis Trading Limited. The company expects to recover A$825,000 from Willis through enforcement proceedings in the Federal Court of Australia, but does not anticipate further recoveries from Alice or Willis due to their financial status. This development may impact Bubs’ financial position and stakeholder interests, as it resolves part of the ongoing arbitration issues.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Limited announced its unaudited financial results for the quarter ending September 2025, highlighting a 30% increase in net revenue to $25.6 million and a gross profit margin of 46.4%. The company achieved an EBITDA of $0.5 million, a significant improvement from a $4.3 million loss in the previous corresponding period. Despite inventory challenges, particularly in the USA, Bubs maintained strong sales through strategic investments in advertising and airfreight. The company is actively managing inventory rebuilds and anticipates resolving shortages by the end of the current quarter. Bubs also expects FDA approval for its products by the end of 2025, which could further enhance its market position.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Limited reported a 30% increase in net revenue to $25.6 million for Q1 FY26, with a gross profit margin of 46.4% and a positive EBITDA of $0.5 million. Despite challenges in inventory and cash flow, particularly in the USA, the company is optimistic about meeting customer demand and achieving growth targets. The USA market showed strong performance, although other regions like China and Australia experienced revenue declines. The company is actively managing inventory issues and expects improvements by the end of the current quarter. Bubs is also awaiting FDA approval for its products by the end of 2025, which could further enhance its market position.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Limited announced the resignation of Mr. Peter Cope as Company Secretary and the appointment of Ms. Olga Smejkalova from Acclime Corporate Services Australia Pty Ltd, effective October 20, 2025. This change in company secretary is significant as Ms. Smejkalova will manage the company’s communications with the ASX, potentially impacting the company’s regulatory interactions and stakeholder communications.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has announced its 2025 Annual General Meeting, which will address several key resolutions. These include the adoption of the remuneration report, re-election of director Paul Jensen, and approval of performance rights for CEO Joe Coote. Additionally, shareholders will vote on granting the company an additional 10% placement capacity and renewing proportional takeover provisions. These resolutions are pivotal for the company’s strategic direction, potentially impacting its governance and financial flexibility.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has announced the date for its 2025 Annual General Meeting, which will be held on November 20, 2025. The company also informed stakeholders that the deadline for director nominations is set for October 21, 2025. This announcement is crucial for shareholders and potential board members as it outlines key dates for corporate governance activities.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. announced a change in the director’s interest, with Paul Jensen acquiring an additional 130,890 ordinary shares through an on-market purchase, increasing his indirect holding to 1,130,890 shares. This transaction reflects a strategic move in the company’s leadership, potentially impacting investor confidence and market perception of Bubs Australia’s growth and stability.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has announced a change in the interest of its director, Paul Jensen, who has increased his indirect holdings in the company by purchasing an additional 500,000 ordinary shares through Taranaki Holdings Ltd, bringing his total to 1,000,000 shares. This move could signal confidence in the company’s future prospects, potentially impacting investor sentiment and market perception positively.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has issued 1,000,000 fully paid ordinary shares to its former CEO and Managing Director, Reg Weine, as part of his sign-on retention performance rights. This issuance was conducted without disclosure under Part 6D.2 of the Corporations Act, and the company confirms compliance with its reporting and disclosure obligations, indicating transparency and adherence to regulatory standards.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has announced the issuance of 1,000,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) as of September 15, 2025. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase its capital base, reflecting its ongoing growth and expansion within the competitive infant nutrition sector.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has announced the cessation of Katrina Rathie as a director, effective September 15, 2025. This change in the board of directors may influence the company’s governance and strategic direction, potentially impacting stakeholders and the company’s position in the infant nutrition market.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. announced the appointment of Joe Coote as a new director, effective from September 15, 2025. The initial director’s interest notice indicates that Coote currently holds no securities or interests in the company, suggesting a fresh perspective without existing financial ties. This appointment could potentially influence the company’s strategic direction and enhance its governance structure, impacting stakeholders and market positioning.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. announced the resignation of Katrina Rathie as Chair and Non-Executive Director. During her tenure, Rathie led the company through a transformative period, achieving its maiden profit and significant revenue growth. Her leadership was instrumental in overhauling employee policies and spearheading diversity initiatives. Rathie’s departure marks the end of a pivotal era for Bubs, as it transitions from a founder-led company to a profitable, well-governed entity with a strong market presence in the USA and Asia.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating its commitment to transparency and accountability in its management and oversight practices. This release is significant as it reinforces Bubs Australia’s dedication to maintaining high governance standards, which is crucial for stakeholder trust and the company’s reputation in the competitive infant nutrition market.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has released its FY25 results, highlighting the company’s performance and strategic direction amidst a challenging economic environment. The announcement underscores the company’s cautious approach due to various risk factors, including regulatory approvals, changing consumer behaviors, and international market demands, which may impact its future operations and market positioning.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Limited reported its first statutory after-tax profit of $5.5 million for the fiscal year ending June 30, 2025, marking a significant turnaround from a $21 million loss in the previous year. The company achieved a 29% increase in total revenue to $102.5 million, driven by strong growth in the USA and China markets, with revenues up 52% and 22% respectively. Despite a slight decline in the Australian market, Bubs maintained its dominant position in the domestic goat IMF market. The company’s financial performance reflects its successful expansion strategy and improved operational efficiency, offering positive implications for stakeholders.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. reported a significant financial turnaround for the fiscal year ending June 30, 2025, with a 29% increase in revenue to $102.5 million and a 124% rise in net profit to $5.17 million. The company’s underlying EBITDA also grew by 103%, indicating improved operational efficiency. This financial performance marks a recovery from a net loss in the previous year, positioning Bubs Australia more robustly in the competitive infant nutrition market.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has announced a webcast for its FY25 results presentation, scheduled for August 29, 2025. This event will provide shareholders with insights into the company’s financial performance and strategic direction, offering an opportunity for questions and engagement, which could impact stakeholder perceptions and market positioning.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. announced the cessation of a significant number of performance rights due to unmet conditions, totaling over 16 million securities. This development may impact the company’s financial structuring and stakeholder confidence, as performance rights are often linked to employee incentives and company performance metrics.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.